Company intelligence / Profile preview

DM Bio

Incheon or nearby city per industrial zone location, Incheon Metropolitan City or Gyeonggi-do region, South Koreagabionline.net ↗

Ownership: Private
Employees: ~25
Development stage: Other

Overview

DM Bio specializes in the development and GMP-compliant commercial manufacturing of mammalian cell culture-based therapeutic proteins and monoclonal antibodies. The company has achieved cGMP approval from Japanese regulators for its facility. Its own biosimilar program includes a psoriasis biosimilar that has received regulatory approval in Japan. The company operates globally as a CDMO partner for biopharma clients.

Therapeutic areas: DermatologyOther
Modalities: Monoclonal antibodyRecombinant proteinBiologicTherapeutic protein
Industry: Biotech

Partnerships

Meiji Seika Pharma/Meiji Holdings Group (joint venture partner until restructuring)Sartorius Stedim Biotech (manufacturing technology partner)

Beyond the preview

Go deeper on DM Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DM Bio.

Explore the full profile